Highlights from the Q2 2008 review of pharmaceutical and biotechnology dealmaking: Despite the dearth in biopharmaceutical financings in the quarter (total money raised was just $2 billion) acquisitions thrived with total M&A volume of $11.8 billion. And biopharma alliance activity reached $2.7 billion in potential deal value during 2008's second quarter with only a handful more deals than the first quarter, but a 43% increase in dollar volume.
In this issue, we present another installment of our quarterly review of pharmaceutical/biotechnology dealmaking—for the second quarter of 2008. Our data are derived from FDC-Windhover's Strategic Transactions database.
Amanda Micklus and Maureen Riordan